

**New business alliance with Dojin Group  
to accelerate research and development of  
regenerative medicine products by using SHED  
and expand SHED-related business**

**July 10, 2020**

# Cautionary Statement

This information material is provided for understanding Gene Techno Science ("GTS"), not for soliciting investment in GTS shares.

Information provided in this material may contain so-called "forward looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Risks and uncertainties include success ratio of R&D projects, new regulations, and rules, relations with partners in the future, etc.



# Executive summary

- Gene Techno Science Co., Ltd. (“GTS”) established new business alliance with Dojin Group, Co., Ltd. to accelerate research and development of regenerative medicine products by using SHED (stem cells from human exfoliated deciduous teeth) and expand SHED-related business (autogenous cell bank services and sale of cell culture supernatant) operated by a wholly-owned subsidiary of the GTS, Advanced Cell Technology and Engineering (hereafter, referred as ACTE)
- Dojin group will acquire ACTE including its affiliate Remcare and handle with autogenous cell bank services, and cell culture supernatant business to such clients as beauty clinics, cosmetic companies and GTS will receive license fees from this new scheme for mid-term period. On the other hand, GTS will retain a key R&D technologies and related assets with regard to SHED owned by ACTE and accelerate R&D activities.

\*The Dojin Group, Co., Ltd. has networks with companies, universities, and government agencies in Japan and overseas, sells pharmaceuticals, medical devices, research reagents, etc., and develops cell culture and storage using regenerative medicine technology.

# Mutual development of two businesses through new business alliance

## Ethical pharmaceutical business



1

• Concentration of management resources through business alliance



• Medium- and long-term license income

• Acceleration of R&D  
• Promotion of business alliance with companies and academia

3

• Awareness improvement of SHED  
• User increase of dental pulp cell bank and culture supernatant

2


• Accumulated clinical development knowledge of SHED  
• Expansion of target diseases of SHED

Positive Growth Cycle

Dojin

Dental Pulp (SHED) Cell Bank (Autogenous cell bank services)  
Culture supernatant from SHED (For beauty clinics and cosmetic ingredient)

Expansion of Business know-how and Networks



+a

# **Gene Techno Science**



***Biotech Engineering Company,  
striving for value creation***